Physician profile
Eric Scott Farbman
NPI 1912965773
$865,605.02
in general payments reported to CMS, 2019-2025
78 companies · $173K in 2025
The $173K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103K · 2020: $51K · 2021: $106K · 2022: $122K · 2023: $178K · 2024: $132K · 2025: $173K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $270K · Honoraria: $72K · Travel and Lodging: $57K · Consulting Fee: $57K · Food and Beverage: $25K · Education: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $269,678.17 |
| Honoraria | $72,443.00 |
| Travel and Lodging | $57,422.64 |
| Consulting Fee | $56,907.50 |
| Food and Beverage | $25,111.80 |
| Education | $1,584.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $303,785.32 | 2019-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $265,963.88 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Acadia Pharmaceuticals INC | $108,261.38 | 2019-2025 | Nuplazid |
| Acorda Therapeutics, INC | $54,185.50 | 2019-2024 | Inbrija, Ampyra |
| Teva Pharmaceuticals USA, INC. | $49,049.76 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Adamas Pharmaceuticals, INC. | $14,401.53 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $14,276.69 | 2019-2025 | Ongentys, Ongentys 50mg Capsules 30, Rytary |
| Medtronic, INC. | $11,062.26 | 2021-2025 | Percept Pc Brainsense, Sensight, Intellis Adaptivestim |
| Boston Scientific Corporation | $8,294.34 | 2019-2025 | Vercise, General - Dbs, Linear |
| Medtronic USA, INC. | $6,621.06 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $6,612.41 | 2019-2021 | |
| Abbott Laboratories | $4,790.95 | 2019-2025 | Infinity |
| Abbvie INC. | $3,039.75 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,750.28 | 2019-2024 | |
| Allergan, INC. | $1,446.88 | 2019-2022 |
Show all 77 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Farbman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.